Omeros Corp. (OMER: Quote) said Tuesday that it plans to offer shares of its common stock in a registered underwritten public offering.
The company also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering solely to cover overallotments, if any.
Omeros said it plans to use the net proceeds of the offering for general corporate purposes, including expenses related to the clinical development of Omeros' two ongoing Phase 3 clinical development programs - OMS302 for use during intraocular lens replacement procedures and OMS103HP for use during arthroscopic partial meniscectomy surgery.
The net offering proceeds may also be used to fund research and development in Omeros' preclinical studies and clinical trials, capital expenditures, working capital and to otherwise advance Omeros' product candidates toward commercialization.
Click here to receive FREE breaking news email alerts for Omeros Corp. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com